A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of A Single Dose of BW-50218 in Healthy Chinese Participants

Led by Shanghai Argo Biopharmaceutical Co., Ltd. · Updated on 2026-06-24

Participants Needed

Research Sites

43 weeks

Total Duration

AI-Summary

A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants

CONDITIONS

A Phase 1 Study of Single-Dose BW-50218 in Healthy Chinese Participants

Age: 18Years - 60Years

All Genders

Healthy Volunteers

Inclusion Criteria:

Capable of providing written informed consent and complying with all study procedures for the duration of the study.
Body weight > 50 kg for males and > 45 kg for females; body mass index (BMI) within a range considered appropriate for study participation by the investigator.
Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.
Male participants with partners of childbearing potential must agree to use effective contraception.

Exclusion Criteria:

Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that, in the opinion of the Investigator, makes the participant unsuitable for participation in the study.
Recent hospitalization or a significant acute medical event.
History of cancer or any long-term medical condition that the study doctor considers clinically relevant.
Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.
Positive test for hepatitis B, hepatitis C, or HIV.

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here